Revvity Inc. has announced a new collaboration with Sanofi to expand its early detection offerings for type 1 diabetes (T1D). The partnership will support the development and clinical validation of a new T1D 4-plex in vitro diagnostic assay, building on Revvity's existing research-use 3-plex assay. Designed for use on Revvity's GSP® instrument, the new high-throughput assay will enable population-level screening using capillary dried blood spot and venous samples. Regulatory submissions for the assay are planned in the U.S., Europe, and other major markets. The collaboration aims to accelerate the adoption of early T1D screening as a new standard of care, improving patient outcomes through earlier intervention.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251002034718) on October 02, 2025, and is solely responsible for the information contained therein.